Ambu A/S (0MJF)
London Exchange · UK · prices in DKK · close of 22 Oct 2026
Key indicators
| Last close | DKK 79.58 |
|---|---|
| 52-week range | 56.40 – 108.60 |
| Return, 1 month / 3 months | +21.9% / +13.4% |
| Return, 1 year / 3 years | −24.4% / +18.8% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 38.4% |
| Worst drawdown (1 year) | -45.8% |
| Average daily value traded | 3.80M DKK |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ambu is a Danish medical device company that develops and manufactures single-use equipment for hospitals and healthcare providers. Its range covers disposable endoscopes for examining the airways and digestive tract, along with anaesthesia and resuscitation products such as face masks, laryngeal masks and breathing aids. The company is based in Denmark and supplies clinicians and medical institutions in many countries, focusing on single-use designs that reduce the need for cleaning and reprocessing between patients.
Ambu A/S trades under the code 0MJF on the London Exchange in UK, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ambu A/S (0MJF) trades on the London Exchange in UK. It last closed at DKK 79.58 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,272 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.4% and over the last three months it rose 13.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 11.2% | ||
| From 52-week high | -26.5% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 13.4% | ||
| 6-month return | 16.3% | ||
| 12-month return, skipping the last month | -37.9% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -45.8% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.80M DKK | ||
| Zero-volume days | 3.3% | ||
| Income | 6 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.5% |
|---|---|
| 1 month | +21.9% |
| 3 months | +13.4% |
| 6 months | +16.3% |
| 1 year | −24.4% |
| 3 years | +18.8% |
| 5 years | −56.8% |
Signals
| 50-day / 200-day average | 71.24 / 71.59 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.94 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Dec 2025 | DKK 0.4100 |
| 5 Dec 2024 | DKK 0.3800 |
| 15 Dec 2021 | DKK 0.2900 |
| 10 Dec 2020 | DKK 0.2900 |
| 18 Dec 2019 | DKK 0.3800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.